RESULTS
2 matches
Article
Astellas bets $1.34B on Audax approach to taming IL-12
Astellas Pharma Inc. has taken an exclusive option to license DAX-044 from Melbourne, Australia-based Audax Biosciences, formerly Onko-innate, in a deal worth up to $1.34 billion, backing the…
Article
Astellas licenses option for Audax’s lead immuno-oncology candidate
Astellas Pharma Inc. and Audax Biosciences Pty Ltd. have entered into an exclusive option and license agreement for Audax’s lead immuno-oncology candidate, DAX-044, a novel immune-targeted IL-12 antibody-cytokine…
EXPLORE
Browse sections
Article
Hiker left harrowing final voicemail for dad before he was killed in horror bear attack
Article
Brits 'tolerate mediocre' as top things they grin and bear revealed
Article
A VIEW OF THE WEEK: They fought for freedom, not just a Wednesday off
Article
China expels record 33 Communist Party members as Xi tightens discipline
Article
Surrey Police Board names new chief constable
Article
Fatwa Issued Against Sara Ali Khan For Visiting Kedarnath, Maulana Shahabuddin Razvi Asks Actress To Repent
Article
BYD sees 28% profit growth for 3Q26, but still falls short of forecasts
Article